NCT06019975 FDG-PET in the Diagnosis of Autoimmune Encephalitis
| NCT ID | NCT06019975 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Milano Bicocca |
| Condition | Autoimmune Encephalitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 90 participants |
| Start Date | 2023-03-01 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 90 participants in total. It began in 2023-03-01 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this retrospective observational study is to compare brain fluorodeoxyglucose-positron emission tomography (FDG-PET) of patients with autoimmune encephalitis, normal controls and patients with Alzheimer's disease (AD). The main question it aims to answer is: •is there a specific pattern of brain metabolism in patients with autoimmune encephalitis Participants data and images will be retrospectively collected from hospital records, and FDG-PET images will be analyzed by means of statistical parametric mapping (SPM). Controls will be selected from validated public databases.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of autoimmune encephalitis according to clinical criteria * Brain magnetic resonance imaging performed between clinical presentation and treatment * Cerebrospinal fluid analysis performed between clinical presentation and treatment * Brain FDG-PET performed between clinical presentation and treatment * Autoantibodies testing performed between clinical presentation and treatment Exclusion Criteria: * Refusal to give consent for the study
Contact & Investigator
Simone Beretta, MD, PhD
PRINCIPAL INVESTIGATOR
University of Milano Bicocca
Frequently Asked Questions
Who can join the NCT06019975 clinical trial?
This trial is open to participants of all sexes, studying Autoimmune Encephalitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06019975 currently recruiting?
Yes, NCT06019975 is actively recruiting participants. Contact the research team at simone.beretta@unimib.it for enrollment information.
Where is the NCT06019975 trial being conducted?
This trial is being conducted at Udine, Italy, Genoa, Italy, Pavia, Italy, Milan, Italy and 2 additional locations.
Who is sponsoring the NCT06019975 clinical trial?
NCT06019975 is sponsored by University of Milano Bicocca. The principal investigator is Simone Beretta, MD, PhD at University of Milano Bicocca. The trial plans to enroll 90 participants.